Infliximab News and Research

RSS

Infliximab is a monoclonal antibody that blocks the action of a cytokine called tumor necrosis factor alfa. It is being studied in the treatment and prevention of weight loss and loss of appetite in patients with advanced cancer. It belongs to the family of drugs called monoclonal antibodies.

500,000 patients have now been treated with REMICADE® worldwide

Centocor, Inc., announced today that more than a half million patients worldwide have now been treated with the anti-TNF agent REMICADE® (infliximab) since it was introduced in the United States five years ago.

21 Apr 2004

FDA accepts REMICADE® (infliximab) for the treatment of early rheumatoid arthritis

Centocor, Inc., announced today that the U.S. Food and Drug Administration (FDA) has accepted its filing of a supplemental Biologics License Application (sBLA) for REMICADE® (infliximab) as first-line therapy, in combination with methotrexate, for the treatment of early rheumatoid arthritis (RA) patients with moderately-to-severely active disease. REMICADE®, in combination with methotrexate, is currently indicated in the U.S. for reducing signs and symptoms, inhibiting the progression of structural damage and improving physical function in patients with moderately-to-severely active RA who have had an inadequate response to methotrexate alone.

6 Apr 2004